Literature DB >> 33717738

An Unusual Presentation of Influenza-Induced Myositis.

Mohamed M Elagami1, Moutaz Ghrewati1, Ibrahim Khaddash1, Gabriel Melki1.   

Abstract

Post-influenza myositis is considered a distinct clinical entity and is associated with muscle pain and elevated muscle enzymes during convalescence. Although the exact mechanism of muscle injury in acute viral myositis is unknown, there are possible mechanisms proposed in the literature. The progression of viral myositis to rhabdomyolysis, although uncommon, can be life-threatening and has been reported with many viruses, most commonly influenza. At our institution, a case of severe influenza-induced myositis prompted us to conduct a literature search focusing on the incidence, pathophysiology, typical presentation, and proper diagnosis of this rare condition.
Copyright © 2021, Elagami et al.

Entities:  

Keywords:  enzymes; inflammation; influenza; myositis; serologic

Year:  2021        PMID: 33717738      PMCID: PMC7943049          DOI: 10.7759/cureus.13196

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  5 in total

Review 1.  Infectious etiologies of rhabdomyolysis: three case reports and review.

Authors:  U Singh; W M Scheld
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

Review 2.  Influenza.

Authors:  Timothy M Uyeki
Journal:  Ann Intern Med       Date:  2017-09-05       Impact factor: 25.391

3.  Postviral myositis: myxovirus-like structures in affected muscle.

Authors:  T P Greco; P W Askenase; M Kashgarian
Journal:  Ann Intern Med       Date:  1977-02       Impact factor: 25.391

Review 4.  NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy.

Authors:  P H Plotz; L G Rider; I N Targoff; N Raben; T P O'Hanlon; F W Miller
Journal:  Ann Intern Med       Date:  1995-05-01       Impact factor: 25.391

Review 5.  Bacterial, fungal, parasitic, and viral myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.